1219741-55-5 Usage
Molecular structure
The compound consists of a pyridine ring with a methyl and a carbonyl group attached to it, as well as a phenyl group substituted with a boron-containing moiety.
Boron-containing moiety
The compound contains a boron atom in a five-membered ring, which gives it unique reactivity and stability properties.
Versatile reagent
Due to its ability to serve as a versatile reagent for the introduction of boron-containing groups into various organic compounds, it is commonly used as a building block in organic synthesis and pharmaceutical research.
Materials science applications
The boron-containing group in this compound makes it useful in materials science for the preparation of boron-containing polymers and other advanced materials.
Check Digit Verification of cas no
The CAS Registry Mumber 1219741-55-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,9,7,4 and 1 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1219741-55:
(9*1)+(8*2)+(7*1)+(6*9)+(5*7)+(4*4)+(3*1)+(2*5)+(1*5)=155
155 % 10 = 5
So 1219741-55-5 is a valid CAS Registry Number.
1219741-55-5Relevant articles and documents
NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
-
Page/Page column 44, (2010/04/25)
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS
-
Page/Page column 90-91, (2010/05/14)
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK- activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
